304 related articles for article (PubMed ID: 33816290)
1. RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma.
Li H; Hu J; Yu A; Othmane B; Guo T; Liu J; Cheng C; Chen J; Zu X
Front Oncol; 2021; 11():642159. PubMed ID: 33816290
[TBL] [Abstract][Full Text] [Related]
2. Genes associated with N6-methyladenosine regulators provide insight into the prognosis and immune response to renal clear cell carcinoma.
Fan G; Wu D; Chen H; Wen Z; Liao L; He S; Yang J
Environ Toxicol; 2024 Feb; 39(2):626-642. PubMed ID: 37555770
[TBL] [Abstract][Full Text] [Related]
3. N6-methyladenosine Regulator-Mediated Immune Genes Identify Breast Cancer Immune Subtypes and Predict Immunotherapy Efficacy.
Zhang MM; Lin YL; Zeng WF; Li Y; Yang Y; Liu M; Ye YJ; Jiang KW; Wang S; Wang S
Front Genet; 2021; 12():790888. PubMed ID: 34976022
[TBL] [Abstract][Full Text] [Related]
4. Expression Profile Analysis of m6A RNA Methylation Regulators Indicates They Are Immune Signature Associated and Can Predict Survival in Kidney Renal Cell Carcinoma.
Fang J; Hu M; Sun Y; Zhou S; Li H
DNA Cell Biol; 2020 Oct; ():. PubMed ID: 33085515
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer.
Liu J; Wang J; Wu M; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
Front Med (Lausanne); 2021; 8():757432. PubMed ID: 35004726
[No Abstract] [Full Text] [Related]
6. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
7. N6-Methyladenosine Writer Gene ZC3H13 Predicts Immune Phenotype and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma.
Guo T; Duan H; Chen J; Liu J; Othmane B; Hu J; Li H; Zu X
Front Oncol; 2021; 11():718644. PubMed ID: 34497769
[TBL] [Abstract][Full Text] [Related]
8. m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma.
Li J; Wang W; Zhou Y; Liu L; Zhang G; Guan K; Cui X; Liu X; Huang M; Cui G; Sun R
Front Cell Dev Biol; 2021; 9():687756. PubMed ID: 34277630
[No Abstract] [Full Text] [Related]
9. N
Li C; Zhu M; Gao C; Lu F; Chen H; Liu J; Zhong W
Front Biosci (Landmark Ed); 2024 Jan; 29(1):33. PubMed ID: 38287827
[TBL] [Abstract][Full Text] [Related]
10. N6-methyladenosine methylation modification patterns reveal immune profiling in pancreatic adenocarcinoma.
Xu H; Yin L; Xu Q; Xiang J; Xu R
Cancer Cell Int; 2022 May; 22(1):199. PubMed ID: 35606813
[TBL] [Abstract][Full Text] [Related]
11. Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas.
Cai Z; Zhang J; Liu Z; Su J; Xu J; Li Z; Meng H; Zhang H; Huang M; Zhao D; Duan C; He X
Ann Transl Med; 2021 Aug; 9(15):1241. PubMed ID: 34532378
[TBL] [Abstract][Full Text] [Related]
12. N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
Zhang Y; Zhu B; He M; Cai Y; Ying X; Jiang C; Ji W; Zeng J
Front Oncol; 2021; 11():710767. PubMed ID: 34458149
[TBL] [Abstract][Full Text] [Related]
13. N6-methyladenosine (m6A) regulatory gene divides hepatocellular carcinoma into three subtypes.
Wei J; Fang DL; Zhou W; He YF
J Gastrointest Oncol; 2021 Aug; 12(4):1860-1872. PubMed ID: 34532134
[TBL] [Abstract][Full Text] [Related]
14. Link between m6A modification and infiltration characterization of tumor microenvironment in lung adenocarcinoma.
Yang S; Li K; Zhang J; Liu J; Liu L; Tan Y; Xu C
Exp Biol Med (Maywood); 2023 Dec; 248(23):2273-2288. PubMed ID: 38166412
[TBL] [Abstract][Full Text] [Related]
15. N6-Methyladenosine-Related Long Non-coding RNA Signature Associated With Prognosis and Immunotherapeutic Efficacy of Clear-Cell Renal Cell Carcinoma.
Ma T; Wang X; Wang J; Liu X; Lai S; Zhang W; Meng L; Tian Z; Zhang Y
Front Genet; 2021; 12():726369. PubMed ID: 34721523
[TBL] [Abstract][Full Text] [Related]
16. Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers.
Li R; Yin YH; Ji XL; Liu X; Li JP; Qu YQ
Front Mol Biosci; 2021; 8():644620. PubMed ID: 34150845
[TBL] [Abstract][Full Text] [Related]
17. Significance of N6-Methyladenosine RNA Methylation Regulators in Immune Infiltrates of Ovarian Cancer.
Gu J; Bi F
Front Genet; 2021; 12():671179. PubMed ID: 34306015
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of m6A modification in immune infiltration, metabolism and drug resistance in hepatocellular carcinoma.
Shi Y; Li K; Yuan Y; Wang C; Yang Z; Zuo D; Niu Y; Qiu J; Li B; Yuan Y; He W
Cancer Cell Int; 2024 Apr; 24(1):138. PubMed ID: 38627760
[TBL] [Abstract][Full Text] [Related]
19. An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment.
Du Y; Ma Y; Zhu Q; Liu T; Jiao Y; Yuan P; Wang X
Front Pharmacol; 2021; 12():707930. PubMed ID: 34248650
[No Abstract] [Full Text] [Related]
20. M6A Classification Combined With Tumor Microenvironment Immune Characteristics Analysis of Bladder Cancer.
Zhu H; Jia X; Wang Y; Song Z; Wang N; Yang Y; Shi X
Front Oncol; 2021; 11():714267. PubMed ID: 34604051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
